Drug Trial Radar · NCT07170917
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Nov 6, 2025
Primary completion
Feb 9, 2027
Study completion Nov 23, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe HS. Study details include: The study duration (per participant) will be up to approximately 164 weeks for participants transitioning into the long-term extension (LTE) period and will be up to approximately 60 weeks for participants not transitioning into the LTE period. The randomized treatment duration will be up to approximately 152 weeks
Conditions
- Hidradenitis Suppurativa
Interventions
BrivekimigDrug
* Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection
PlaceboDrug
* Pharmaceutical form: Solution for injection in vial * Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Up to Week 16
Locations
85 sites in 19 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists- Site Number : 8400019
Phoenix, Arizona · Recruiting
Mayo Clinic in Arizona - Scottsdale- Site Number : 8400014
Scottsdale, Arizona · Recruiting
Northridge Clinical Trials - Northridge- Site Number : 8400005
Northridge, California · Recruiting
Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8400001
Fort Myers, Florida · Recruiting
FXM Clinical Research - Miami- Site Number : 8400017
Miami, Florida · Recruiting
FXM Clinical Research - Miramar- Site Number : 8400004
Miramar, Florida · Recruiting
Advanced Medical Research - Atlanta- Site Number : 8400011
Atlanta, Georgia · Recruiting
Georgia Skin & Cancer Clinic- Site Number : 8400009
Savannah, Georgia · Recruiting
The Iowa Clinic West Des Moines Campus- Site Number : 8400007
West Des Moines, Iowa · Recruiting
Louisiana Dermatology Associates- Site Number : 8400006
Baton Rouge, Louisiana · Recruiting
Washington University- Site Number : 8400010
St Louis, Missouri · Recruiting
JDR Dermatology Research- Site Number : 8400012
Las Vegas, Nevada · Recruiting
Icahn School of Medicine at Mount Sinai- Site Number : 8400021
New York, New York · Recruiting
University of North Carolina at Chapel Hill- Site Number : 8400025
Chapel Hill, North Carolina · Recruiting
Clinical Partners- Site Number : 8400002
Johnston, Rhode Island · Recruiting
AMR Clinical South Strand, South Carolina- Site Number : 8400018
Myrtle Beach, South Carolina · Recruiting
Ut Southwestern Medical Center, Department Of Dermatology- Site Number : 8400022
Dallas, Texas · Recruiting
Investigational Site Number : 0360003
Liverpool, New South Wales, Australia · Recruiting
Investigational Site Number : 0360002
Melbourne, Victoria, Australia · Recruiting
Investigational Site Number : 1240008
Edmonton, Alberta, Canada · Recruiting
Investigational Site Number : 1240007
Sherwood Park, Alberta, Canada · Recruiting
Investigational Site Number : 1240003
Kelowna, British Columbia, Canada · Recruiting
Investigational Site Number : 1240001
Hamilton, Ontario, Canada · Recruiting
Investigational Site Number : 1240009
Toronto, Ontario, Canada · Recruiting
Investigational Site Number : 1240005
Québec, Quebec, Canada · Recruiting
Investigational Site Number : 1520004
Talcahuano, Biobio, Chile · Recruiting
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1520005
Santiago, Reg Metropolitana de Santiago, Chile · Recruiting
Investigational Site Number : 1560002
Chengdu, China · Recruiting
Investigational Site Number : 1560001
Guangzhou, China · Recruiting
Investigational Site Number : 1560004
Shanghai, China · Recruiting
Investigational Site Number : 1560005
Ürümqi, China · Recruiting
Investigational Site Number : 2030002
Ostrava, Czechia · Active not recruiting
Investigational Site Number : 2030003
Ostrava, Czechia · Active not recruiting
Investigational Site Number : 2030001
Prague, Czechia · Active not recruiting
Investigational Site Number : 2030004
Prague, Czechia · Active not recruiting
Investigational Site Number : 2500001
Antony, France · Recruiting
Investigational Site Number : 2500004
Bezannes, France · Recruiting
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.